Hafrun Fridriksdottir Sells 933 Shares of Teva Pharmaceutical Industries Ltd (TEVA) Stock
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) VP Hafrun Fridriksdottir sold 933 shares of the stock in a transaction on Friday, November 30th. The stock was sold at an average price of $21.76, for a total value of $20,302.08. Following the completion of the sale, the vice president now directly owns 9,762 shares in the company, valued at $212,421.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Shares of TEVA traded down $0.82 during trading hours on Thursday, reaching $19.73. 8,610,703 shares of the company’s stock traded hands, compared to its average volume of 8,660,157. The firm has a market capitalization of $20.90 billion, a price-to-earnings ratio of 5.02, a price-to-earnings-growth ratio of 6.20 and a beta of 0.74. The company has a debt-to-equity ratio of 1.75, a quick ratio of 0.61 and a current ratio of 0.94. Teva Pharmaceutical Industries Ltd has a twelve month low of $14.05 and a twelve month high of $25.96.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, November 1st. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.53 by $0.11. The firm had revenue of $4.53 billion for the quarter, compared to analyst estimates of $4.54 billion. Teva Pharmaceutical Industries had a positive return on equity of 21.83% and a negative net margin of 54.67%. Teva Pharmaceutical Industries’s revenue was down 19.4% compared to the same quarter last year. During the same period in the previous year, the company earned $1.00 earnings per share. Analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.82 EPS for the current fiscal year.
TEVA has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $25.00 target price on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 16th. Mizuho reaffirmed a “buy” rating and issued a $28.00 target price on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 16th. Credit Suisse Group lowered Teva Pharmaceutical Industries from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $25.00 to $23.00 in a report on Friday, September 7th. BTIG Research raised Teva Pharmaceutical Industries from a “sell” rating to a “neutral” rating in a report on Monday, September 17th. Finally, Wells Fargo & Co set a $23.00 price target on Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Monday, September 17th. Three research analysts have rated the stock with a sell rating, fifteen have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries presently has a consensus rating of “Hold” and a consensus price target of $21.94.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Story: What are the Different Types of Leveraged Buyouts?
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.